End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article


ABSTRACT

Selecting the most appropriate end points for clinical trials is important to assess the value of new treatment strategies. Well-established end points for clinical research exist in oncology but may not be as relevant to the older cancer population because of competing risks of death and potentially increased impact of therapy on global functioning and quality of life. This article discusses specific clinical end points and their advantages and disadvantages for older individuals.

Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations but ideally need to be confirmed in phase III trials, which are unfortunately often hindered by the severe heterogeneity of the older cancer population, difficulties with selection bias depending on inclusion criteria, physician perception, and barriers in willingness to participate. All clinical trials in oncology should be without an upper age limit to allow entry of eligible older adults. In settings where so-called standard therapy is not feasible, specific trials for older patients with cancer might be required, integrating meaningful measures of outcome. Not all questions can be answered in randomized clinical trials, and large observational cohort studies or registries within the community setting should be established (preferably in parallel to randomized trials) so that treatment patterns across different settings can be compared with impact on outcome. Obligatory integration of a comparable form of geriatric assessment is recommended in future studies, and regulatory organizations such as the European Medicines Agency and US Food and Drug Administration should require adequate collection of data on efficacy and toxicity of new drugs in fit and frail elderly subpopulations.

J Clin Oncol 31:3711-3718. © 2013 by American Society of Clinical Oncology

INTRODUCTION

The choice of appropriate end points is important to assess the benefit of therapy. In oncology, there are well-established clinical end points for clinical research in randomized clinical trials (RCTs); in the curative/adjuvant setting, disease-free survival (DFS) and overall survival (OS) are the most recognized and well accepted. For metastatic solid tumors, progression-free survival (PFS), time to tumor progression (TTP), time to treatment failure (TTF), response rate (RR), and OS are the most commonly used end points.

A caveat is that the definitions of these so-called standard outcomes have varied in different trials in the past, challenging the ability to compare across studies and provide evidence-based care. There are international efforts to streamline this, such as the DATECAN (Definition for the Assessment of Time-to-Event End Points in Cancer Trials) project.1

However, these standard end points may not be the most appropriate to balance the benefits with the risks of therapy in older patients with cancer, because older patients often die as a result of other diseases, and relapse will not always affect survival, whereas cancer-directed therapy can sometimes cause severe acute or chronic toxicities and decreased quality of life (QoL). For young patients with familial/social obligations (eg, toward young children), prolongation of life might be the most important end point; however, older adult patients with incurable disease may prefer QoL above quantity of life, especially if treatment also has an impact on their functional capacity and ability to carry out...
daily tasks, their cognitive function, their social situation/capability to stay at home, or their caregiving abilities. Therefore, there is a need for delineation of relevant clinical end points for older individuals, which can then be uniformly incorporated into future clinical trials.

The best-established form of clinical trial design is the RCT. When designing RCTs for older patients with cancer, selection of what should be the standard arm may vary because this can be different for fit, vulnerable, and frail patients. As a result, it will often not be possible to have the same standard arm for all older patients, so other trial designs should be considered, especially for vulnerable and frail patients.

This article describes several potential outcome measures/end points and their advantages and disadvantages for elderly-specific clinical trials and discusses potential trial designs that could be used to greatly expand evidence-based treatment outcomes for the older population with cancer.

### OUTCOME MEASURES/END POINTS FOR CLINICAL TRIALS IN OLDER INDIVIDUALS

#### OS

OS is considered the gold standard in clinical trials, especially when evaluating the superiority of new treatments; other end points such as PFS and DFS are commonly used to report on clinical benefit, but this has been subject to criticism (Table 1). Surrogacy of these end points for OS has been demonstrated in some specific settings and is under investigation in others. Compared with younger patients, elderly patients with cancer often present with significant comorbidities and therefore die as a result of other, non–cancer-related diseases more frequently. Elderly patients are more likely to experience severe toxicities from cancer-directed therapies, including treatment-related mortality. Non–disease-related deaths and treatment discontinuation/reduced dosage because of toxicity might dilute treatment benefit, and larger sample sizes would be needed to demonstrate treatment effects. It should be emphasized that this diluted benefit is an accurate estimate of the true clinical benefit in the older population, and larger sample sizes are the price society has to pay if it wants to ensure that older patients are not subjected to toxic therapies that provide no tangible clinical benefit. The mentioned concerns have resulted in age limits and stringent inclusion criteria, leading to the exclusion of large numbers of older patients from clinical trials. Although excluding older patients with comorbidities could help a trial determine whether a benefit from treatment exists (especially if the benefit is small), this approach limits generalizability of the treatment for the vast majority of cancers, where most of the patients are older. On average, the trial population in chemotherapy trials is 5 to 10 years younger than the general population with the disease. Because there are no regulatory requirements for establishing the efficacy or toxicity of new therapies in older adults, the limited data in this population ultimately lead to the risk of expensive treatments being used in the older, less studied population, resulting in higher toxicity and smaller benefit than in younger patients with cancer.

#### Disease-Specific Survival

Whereas primary end points such as OS or PFS would still be suitable to provide a realistic estimation of treatment benefit in the targeted population in the presence of competing risks, measuring cancer-specific end points such as disease-specific survival (DSS) and performing competing risks analyses could generate crucial data. Nout et al nicely demonstrated that including or excluding non–breast cancer–related deaths and contralateral breast cancer significantly affected outcome reporting in early breast cancer. DSS better indicates how many patients die as a result of disease and how many die as a result of other causes. A prerequisite to using DSS as the primary end point is that the cause of death can be reliably ascertained, and other causes of death are not related to the treatment. In that case, DSS as the primary end point might help in requiring a smaller sample size. However, a reduction in the risk of one type of event (eg, death resulting from cancer) can lead to an increase in the number of observed events for competing types, just because patients remain at risk for those events for a longer period. At any rate, information on cause of death should always be reported to distinguish cancer deaths from treatment-related deaths and deaths resulting from other causes. We recommend reporting DSS always in addition to OS.

#### Coprimary End Points

Coprimary end points should also be considered because this allows capturing more than efficacy alone. Multiple single end points can be chosen as coprimary end points of equal importance, and a statistical design can be built to test each separately. However, coprimary end points also have disadvantages; statistical design is difficult because the correlation between the different end points is rarely known. Moreover, if the trial objective is to have positive results for at least one or all coprimary end points, the type I or II error, respectively, must be adjusted for multiple testing, which necessitates in increase of sample size.

#### Composite End Points

Composite end points are another way of integrating other aspects into the end point, such as QoL, treatment effects on disease-related symptoms, functional capacity, and ability to carry out daily tasks. As the International Conference on Harmonisation stated, composite end points avoid the need for arbitrary choice and deal with multiplicity in an efficient manner when several outcome measures are of equal importance to the patient. A composite end point in an RCT consists of multiple single end points that are combined so that an event is indicated if any of the end points occurs. Composite end points have sometimes been used in oncology (eg, skeletal-related events in clinical trials with bisphosphonates or denosumab) but have been more widely used and studied in other medical disciplines, mainly in cardiology. Major advantages of a composite end point are the simplicity of the statistical design, which is based on a single end point (ie, the composite one), and the resultant increase in statistical efficiency. However, there are also risks, and caution must be applied. The major possible issues include: lack of a strong rationale given for the composite (ie, mixture of end points with different clinical importance; eg, death and hospital admission), difficulty in interpretation of the results in case of positive results on the composite but observed divergent effects on the components, and inadequate or incorrect reporting of the results (eg, declaring positive effects on the most important component when statistical significance is only reached for the composite, and when the more important component, such as death, accounts only for a minority of the events). Less frequent but important to consider is the situation in which negative results can be observed for the composite, while
Table 1. Relevant End Points in Clinical Trials in the Older Cancer Population

<table>
<thead>
<tr>
<th>End Point</th>
<th>Definition</th>
<th>Current Situation</th>
<th>Pro</th>
<th>Con</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS: time or proportion</td>
<td>Time from diagnosis of treatment situation/study entry until death or rate of patients alive at specified time point</td>
<td>Considered gold standard in clinical trials, especially when evaluating superiority of new treatments</td>
<td>Remains hardest end point, also in elderly</td>
<td>Oncologic relevance in elderly can be hampered by increased number of non-cancer-related deaths (all life ends with death)</td>
</tr>
<tr>
<td>DSS: time or proportion</td>
<td>Time from diagnosis of treatment situation/study entry until death resulting from index disease or rate of patients without death related to index disease at specified time point</td>
<td>Important to collect in addition to OS because it gives better insight into contribution of non-cancer-related deaths</td>
<td>Cancer treatment primarily aims at decreasing cancer death</td>
<td>Some cancer treatments might also influence non-cancer-related deaths (eg, treatment-related mortality) May lead to overestimation of true benefit for patients in presence of competing risks (eg, treatment benefit in localized prostate cancer) Reason for death will be of no/minor meaning for patients Reason for death can remain unclear</td>
</tr>
<tr>
<td>Coprimary end points</td>
<td>Combination of ≥ two equal primary end points</td>
<td>Rarely used in oncology</td>
<td>Allows capturing more than efficacy alone</td>
<td>Difficult statistical design because correlation between different end points is rarely known Might increase sample size</td>
</tr>
<tr>
<td>Composite end points</td>
<td>Combination of different end points in one defined end point</td>
<td>Rarely used in oncology</td>
<td>Can take into account multiple dimensions in definition of treatment benefit, including efficacy and toxicity Simple and efficient statistical design Allows separate reporting of different end points</td>
<td>Requires individual components of composite that are clinically meaningful and of similar relative importance Difficult interpretation if there are divergent results for each component separately</td>
</tr>
<tr>
<td>TFFS and TTF: time or proportion</td>
<td>TFFS is time elapsing between random assignment and early treatment discontinuation because of any reason (including disease progression, treatment toxicity, early death), disease progression, death (resulting from any cause), or any other event of interest; TTF is similar, but death resulting from other cause is not considered an event</td>
<td>Often used in addition to OS</td>
<td>Integrates efficacy and toxicity</td>
<td>Difficult to distinguish between efficacy and toxicity (eg, toxic but effective) Treatments might be stopped for other reasons (eg, chemotherapy holiday)</td>
</tr>
<tr>
<td>QoL-related end points: level at specified time point or time until deterioration compared with baseline</td>
<td>Evaluation of QoL through validated instruments at baseline and during course of disease/treatment/study</td>
<td>Often used as secondary end point in clinical trials but should be promoted as primary end point or part of composite end point</td>
<td>QoL may be more important than duration of life for many older individuals</td>
<td>Difficult to measure and identify clinically relevant cutoffs that determine whether therapy is worthwhile</td>
</tr>
<tr>
<td>Maintenance of functional capacity/dependence: level at specified time point or time until deterioration compared with baseline</td>
<td>Evaluation of evolution of functioning and (in)dependence through validated instruments during course of disease/treatment/study</td>
<td>Rarely measured in oncology trials but crucial to include</td>
<td>Main contributor to QoL in elderly patients with cancer</td>
<td>No general consensus on optimal measurement or clinically relevant cutoffs determining whether therapy is worthwhile</td>
</tr>
</tbody>
</table>

Abbreviations: DSS, disease-specific survival; OS, overall survival; QoL, quality of life; TFFS, treatment failure–free survival; TTF, time to treatment failure.

statistical significance can be reached for the most important component. The pros and cons of composite end points have been summarized by Kleist.19 Use of this approach is usually justified under the following assumptions:

- The individual components of the composite are clinically meaningful and of similar relative importance to clinical care.
- The expected effects on each component are similar based on clinical/biologic plausibility (which is, in the end, the rationale for using a composite end point).
- For the study to be ultimately positive, the clinically more important components of a composite end point should at least not be affected negatively.
All components of a composite end point should also be analyzed separately and reported as such. The separate reporting of end points is also essential to facilitate cross-study comparisons (although there are also intrinsic limitations to this) or to generate assumptions for designing future trials. It is important to mention that for the US Food and Drug Administration, a regulatory end point should clearly distinguish the efficacy of the drug from toxicity, patient or physician withdrawal, or patient intolerance.

An interesting example of a composite end point in older individuals is therapeutic success. This end point combines efficacy, toxicity, and patient compliance with treatment and has been defined as a patient receiving at least three cycles of chemotherapy, at the planned dose (without dose reduction) and schedule (no treatment delay beyond 2 weeks), and having a response (either complete or partial) without experiencing grade 3 or 4 toxicity according to the Common Toxicity Criteria criteria. Variations of this design are possible, such as defining therapeutic success as being progression free at a fixed time point without having grade 3 or 4 nonhematologic or grade 4 hematologic toxicity. This seems to be an attractive end point in settings where significant differences in toxicity between two treatments are expected and requires further exploration. Looking simultaneously at toxicity and efficacy can be a disadvantage as well as an advantage; therapies might be temporarily toxic, requiring dose reduction, but might be efficacious. Dose, toxicity, and response are related (eg, in patients with non–small-cell lung cancer, those with a higher rate of hematologic toxicity survive longer).

Another example is the use of overall treatment utility (OTU) as an end point in the FOCUS (Fluorouracil, Oxaliplatin, and CPT11 [irinotecan]—Use and Sequencing) trial of older patients with metastatic colorectal cancer, in which good OTU indicated no clinical or radiologic evidence of disease progression and no major negative treatment effects in terms of toxicity or patient acceptability. Intermediate OTU signified either clinical deterioration but no negative treatment effect or a significant negative treatment effect but no clinical deterioration. Poor OTU indicated both clinical deterioration and a major negative treatment effect or death.

Treatment Failure–Free Survival and TTF

Treatment failure–free survival (TFSS) and TTF are well-known examples of composite end points and could also be interesting end points to consider for clinical trials in the elderly. TFSS is defined as the time that elapses between random assignment and early treatment discontinuation because of any reason (including treatment toxicity and patient refusal of further treatment), disease progression, death resulting from any cause, or any other event of interest. TTF is similar, but only disease-specific and treatment-related deaths are considered events. Treatment-related toxicity is a major issue in elderly patients with cancer, especially those with advanced disease stages where the goal of treatment is palliation rather than cure. TFSS and TTF provide an opportunity to take into account the role of toxicity and not concentrate only on efficacy. This is important because older patients are less willing than younger patients to continue treatments with severe toxicities, especially if these have functional consequences that limit independence. One limitation, however, is that in some situations, treatment breaks are introduced not because of toxicity or progression but to provide a period without chemotherapy (ie, chemotherapy holiday), although this can be handled by not considering these breaks as treatment failures. Another limitation is that early treatment discontinuations are still considered failures in situations where significant toxicity occurs, but patients have good disease outcomes (perhaps with improvement of toxicities) thereafter.

QoL-Related End Points

The main goal of cancer treatment, certainly in the palliative setting, should be to reduce discomfort related to or caused by cancer progression and its related consequences (eg, loss of functionality, inability to stay at home, deterioration of QoL). Health-related QoL (HRQoL) is a major concern for patients with cancer, and it can be affected by symptoms caused by cancer as well as by treatment-induced toxicity. For many older patients, the goal of cancer-directed treatment is not just how much additional time they can gain but how valuable that time is. Elderly patients are less willing to compromise their HRQoL for the potential for increased survival. Thus, HRQoL may be an appropriate outcome for elderly-specific trials, but it remains to be defined how to measure or quantify HRQoL optimally, how to quantify the different domains of HRQoL in one score, and which cutoffs are relevant as end points for clinical trials, although a 10-point decrease (on score of 100) is frequently used as relevant change. The EORTC (European Organisation for Research and Treatment of Cancer) QoL Group recently developed an elderly-specific QoL module, which adds specific QoL-related aspects in older individuals to the general EORTC Quality of Life Questionnaire C30. HRQoL should be captured in all trials of palliative chemotherapy in older patients regardless of the primary end point of the trial. The Q-TWIST (quality-adjusted time without symptoms of disease or toxicity of treatment) approach measuring quality-adjusted survival is another QoL–related end point, which partitions the survival time of the patient into three consecutive health states (ie, time with toxicity resulting from treatment, time without symptoms of disease or toxicity, and time from progression/relapse to death) and assigns utility weights to each state. The Q-TWIST value is the sum of the weighted health state durations and is used for treatment comparisons. This approach quantitatively adjusts periods in which treatment toxicities or symptoms of disease progression are present to reflect the potentially reduced value for the patient. In principle, this is a valuable approach for older patients with cancer, but the great difficulty lies in determining or quantifying the weight factor for QoL during the different periods.

Preservation of Functional Capacity/Independence

In a similar way, maintenance of function and independence should be one of the major principles of cancer management in the elderly. A negative impact on a patient’s functional capacity will have a negative impact on survival as well. The prolongation of active life expectancy seems much more important than the prolongation of life expectancy as such. The GERICO (French Geriatric Oncology Group) trial nicely showed that functionality measured by instrumental activities of daily living does not decrease significantly (by ≥ two points) in older patients with breast cancer receiving adjuvant chemotherapy. Using single or multiple domains of geriatric assessment as outcome events would also be of great value to clinicians.

Surgical Trial End Points

Several trials in the surgical field, including elderly-specific trials such as the PACE (Pre-operative Assessment of Cancer in the Elderly)
are relevant but should be accompanied by information on longer-term outcome end points, as we have discussed here.

### TRIAL DESIGN IN OLDER PATIENTS WITH CANCER

**Trials for Older Patients Versus Trials Without Upper Age Limit**

Table 2 lists issues in clinical trial design in older patients with cancer. Clinical trials need to be representative of the whole population in whom the treatment will be used later, which is not the case at present. Several studies have shown that there is substantial underrepresentation of older patients in clinical trials. The differential effects of aging on organ function and the variety of comorbidities that characterize the older population result in significant heterogeneity. This variance could result in considerable differences in the efficacy and safety of cancer treatments. For studies using therapy regimens expected to be used in all age categories, patients should be enrolled across the entire age spectrum, and a minimum cohort of elderly patients should be required. If treatment regimens are expected to be tolerated by only fit older patients or younger patients, severe selection bias will be present, and conclusions from these kinds of trials will not be generalizable to the whole population, especially the frail elderly. It is important to capture the fitness status of the older patients enrolled onto a clinical trial to provide information about the generalizability of the results. Documentation of the nonincluded population is also important. One option for ensuring sufficient accrual of older patients could be to require registration trials to remain open after they have met their target accrual until a minimum cohort of elderly patients is enrolled. It should be noted that older fit patients are likely included in clinical trials and so should likely receive the standard treatments. However, it is clear that several standard treatments administered to younger patients are not suitable for unfit or frail elderly adults (and sometimes even fit elderly adults) because of expected higher or unacceptable risk of toxicity or other competitive risks determining the long-term prognosis. For example, allogeneic bone marrow transplantation; high-dose cytarabine, anthracycline, or cisplatin; major surgery; and concurrent chemoradiotherapy are treatments generally reserved for younger or sometimes fit older patients. In this setting, elderly-specific trials are certainly needed, because there is no clear standard therapy in this group of patients, who are not likely to tolerate the standard therapy administered to fit patients. In frail older patients, separate clinical trials could be designed because these patients could be better served by trials comparing modified approaches (eg, adapted chemotherapy/biologic agents) with pure palliative/supportive care. For vulnerable patients, a possible trial design could include standard therapies versus less aggressive therapies or no therapy, depending on the setting.

Randomized phase III trials remain the gold standard for clinical research, in older as well as younger people. However, designing these trials that address heterogeneity in all elderly populations might be challenging for many reasons (insufficient interest from sponsors/investors, difficulty in finding sufficient numbers of patients, and so on). Often, phase III data exist only for younger populations. Randomized phase II trials can provide insight into the range of efficacy and toxicity in older populations. If the treatment is too toxic, this would be established in a phase II trial. If a phase II trial in an older (nonfit) population shows that the toxicity is acceptable and confirms efficacy in the same range as previous phase III trials in younger people, there might not be a need to repeat the phase III trial again in an older (nonfit) population. However, if the phase II results are indeterminate concerning toxicity and/or efficacy, then confirmation in a phase III trial is likely. Randomized phase II trials in specific subsets of older patients can thus potentially provide relevant information. In these cases, physical status (frailty and vulnerability) could be used as a stratification factor to explore the benefit of treatment in different older populations. Often, no real standards exist for this population (because standard therapy for that disease/indication is expected to be too intense for that person), and all treatments/study arms could actually be seen as experimental arms. Although it might be difficult to select a control arm in a randomized phase II trial, one possibility would be to make the control arm the physician’s decision. Because of the methodologic difficulties of defining appropriate control arms for the reasons mentioned in this article, randomized phase II trials might sometimes turn out to be infeasible. A pragmatic option for frail patients could be to perform only single-arm phase II studies with toxicity as an end point, allowing indirect comparison of toxicity (and efficacy) with fit young/old populations from previous studies. This kind of study could provide relevant information if the appropriate end points (HRQoL, functionality, and so on) are included but would be scientifically much less robust than randomized phase II or III studies. Nevertheless, this type of study is sometimes the only feasible option, and regimens studied this way, such as the R-miniCHOP (rituximab plus low-dose cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen in patients age > 80 years with diffuse large B-cell lymphoma, have been adopted in clinical care because higher-level data are lacking.

**Table 2. Issues in Clinical Trial Design for Older Patients With Cancer**

| RCTs remain gold standard when possible |
| Clinical trials should preferably integrate whole age range, including fit and frail older individuals |
| Elderly-specific clinical trials in older patients with cancer are required if standard therapy is different from that for younger patients |
| Trials of treatment strategy comparing different strategies (eg, therapy versus supportive care) should be encouraged |
| Randomized phase II or even single-arm phase II trials in specific subsets of older patients can provide insight into range of efficacy and toxicity in older populations but ideally should be confirmed in large phase III trials, which might be hard to perform for various reasons (eg, insufficient interest from sponsors/investors, difficulty in finding sufficient numbers of patients) |
| Not all questions can be answered with randomized trials, and large observational cohort studies or registries in community can provide further insight for frail population with less selection bias (preferably in parallel with or linked to RCTs) |
| Comparable/uniform geriatric assessment should be integrated into future trials in geriatric oncology |
| Regulatory authorities should require evaluation of efficacy and safety of new drugs in older and frail patients as well as in younger patients |

Abbreviation: RCT, randomized clinical trial.
Aging is a highly individualized process that results in several changes in organ function, affecting the pharmacokinetics of anticancer drugs. New drugs could, for instance, be studied in amended phase I studies in populations with higher levels of comorbidity or functional limitations in parallel with standard phase I trials or after the drugs have shown promising results in the general population. An approach in the same line is to design phase I/II–type trials with progressively increasing inclusion criteria. The regimen of interest is first administered to patients in good condition, then in cohorts with increasing levels of functional limitations or comorbidities. This would provide evidence-based thresholds for dose reductions or regimen changes. Risk indicators that could be used for this approach include the CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) score, the CARG (Cancer and Aging Research Group) score, or criteria such as those used in lymphoma studies.

Although incorporating geriatric assessment into oncology trials is usually feasible, the major obstacle to using this as a stratification or even randomization factor is the exact/optimal definition of frailty or vulnerability. Balducci and Extermann formulated an operational definition of frail, fit, and vulnerable patients in 2000 that is commonly used in the oncology world but has significant shortcomings; unfortunately, 10 years later, it is still not clear which are the best criteria and tests to be used to make this stratification.

Trails of Treatment Regimens Versus Trials of Treatment Strategies Versus Observational Cohort Studies

Randomized trials of treatment regimens comparing treatment A versus treatment B can provide important information. The CALGB (Cancer and Leukemia Group B) 49907 adjuvant breast cancer trial, for instance, showed that classical adjuvant chemotherapy (AC [doxorubicin and cyclophosphamide] or CMF [cyclophosphamide, methotrexate, and fluorouracil]) was clearly superior to so-called soft chemotherapy with capecitabine. New drugs also need to be tested specifically for older patients. New drugs could, for instance, be studied in amended phase I studies in populations with higher levels of comorbidity or functional limitations in parallel with standard phase I trials or after the drugs have shown promising results in the general population. An approach in the same line is to design phase I/II–type trials with progressively increasing inclusion criteria. The regimen of interest is first administered to patients in good condition, then in cohorts with increasing levels of functional limitations or comorbidities. This would provide evidence-based thresholds for dose reductions or regimen changes. Risk indicators that could be used for this approach include the CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) score, the CARG (Cancer and Aging Research Group) score, or criteria such as those used in lymphoma studies.

Incorporation of Geriatric Assessment Into Clinical Trials

Geriatric assessment has not been used often in previous clinical trials, but it should become more frequently required in the future. Without geriatric assessment information, it is impossible to evaluate which older individuals were included in a trial (eg, fit patients only or fit as well as frail patients), limiting extrapolation of the study data to the general older population. This should be mandatory in registration trials and elderly-specific trials and should be encouraged in all trials including older people. However, many different forms of geriatric assessment exist, which complicates comparisons across trials. It is important to agree on a (more or less) uniform or at least comparable evaluation of the older population. EORTC has made an attempt by providing a minimal data set for geriatric assessment to be included in clinical trials, and CALGB has also demonstrated the feasibility of a mainly self-administered tool in its trials, but there are other options, and it is important to continue international discussion on this topic.

Eligibility Criteria

The generally long list of inclusion and exclusion criteria during the last decade has led to selection bias and exclusion of older patients. Exclusion criteria are not based on a high level of evidence. In clinical trials, especially those focusing on older patients with cancer, an attempt should be made to have as few inclusion and exclusion criteria as possible. A National Institutes of Health team concluded that decreasing function and comorbidity restrictions can dramatically increase elderly accrual to clinical trials.
Europe | Medicine | and | US | Food | and | Drug | Admin | istration | Geriatric | Investigation | Plan

In the medical care of pediatric patients, the European Medicines Agency (EMA) has established a pediatric investigation plan to ensure that drugs are examined appropriately in the pediatric population. There is a need for a global strategy within the EMA/US Food and Drug Administration (FDA) to do the same in the older population. Compulsory use of uniform geriatric assessment and frailty tools in drug registration trials could be helpful in establishing a better view of the fitness of older patients included in clinical trials. The EMA/FDA could require adequate representation of older adults in registration trials if applicable (with information from geriatric assessment) or require postmarketing studies in the general older population. The EMA recently established a geriatric expert group for this purpose. Longitudinal as well as baseline evaluation of geriatric parameters (eg, functionality, social situation, QoL) is crucial to better understanding the impact of new therapies on older individuals and to improving care for this important population.

Choosing end points for clinical trials in older patients with cancer requires careful reflection on the ultimate goals of therapies. OS is a crucial end point, but DSS should also be recorded in trials where older patients with cancer are included, because deaths resulting from other causes (eg, other diseases, treatment toxicity) occur much more frequently in the older population. Composite end points allow the integration of multiple dimensions in addition to efficacy (eg, QoL, evolution of functionality) into the definition of treatment benefit and have clear advantages in RCTs involving older patients with cancer, such as simplicity of statistical design and statistical efficiency. Composite end points are not feasible in all settings, but they are justified if the individual components of the composite are clinically meaningful and of similar relative importance to clinical care. QoL and preservation of functional capacity and independence are important for the older population and should be included more often as end points in clinical trials in this population.

Although clinical trials in principle should include the entire age range of the population, the heterogeneity of this population generally does not allow the capture of the whole older population, leading to selection bias and difficulty in drawing firm conclusions for the elderly killer who are often not included. Specific trials for subgroups of older patients with cancer are needed, with additional pharmacokinetic studies if required, and with appropriate control arms depending on the setting. Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations, but ideally they should be confirmed in large phase III trials that are unfortunately often hindered by insufficient interest from sponsors/investors or difficulty in finding sufficient numbers of patients. Large observational cohort studies in the nonfit older population should be considered, preferably linked to randomized trials, to capture the nonincluded population. Incorporation of a preferably uniform geriatric assessment in elderly-specific or registration trials is crucial to better understanding the effect of treatments in different elderly populations. Regulatory authorities including the EMA/FDA should require geriatric assessment information and adequate representation of older adults, including patients of different health statuses such as vulnerable and frail patients, in trials. Better clinical trial design is crucial to understanding the impact of new therapies on older individuals and to improving care for this important population.

REFERENCES

4. Lichtman S: Clinical trial design in older adults, including patients of different health statuses such as frailty and comorbidity: Significance for the prognostic and comorbidty: Significance for the prognostic classification of cancer. Cancer 77:834-842, 1996

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author’s immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: None Honoraria: None Research Funding: Arti Hurria, Celgene, GlaxoSmithKline Expert Testimony: None Patents: None Other Remuneration: None

AUTHOR CONTRIBUTIONS

Conception and design: Hans Wildiers, Murielle Mauer, Ulrich Wedding Collection and assembly of data: All authors Data analysis and interpretation: All authors Manuscript writing: All authors Final approval of manuscript: All authors
14. Offen W, Chuang-Stein C, Dmitrienko A, et al: Multiple co-primary endpoints: Medical and statisti-
cal solutions—A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and
15. ICH Harmonised Tripartite Guideline: Statisti-
cal principles for clinical trials—International Confer-
ence on Harmonisation E9 Expert Working Group.
Stat Med 18:1905-1942, 1999
16. Lipton A, Fizazi K, Stopeck AT, et al: Superior-
ity of docetaxel over zoledronic acid for prevention of
skeletal-related events: A combined analysis of 3
pivotal, randomised, phase 3 trials. Eur J Cancer
48:3082-3092, 2012
precision but with greater uncertainty? JAMA 289:
2554-2559, 2003
tion, reporting, and interpretation of composite
outcomes in clinical trials. Systematic review.
BMJ 341:c3920, 2010
19. Kleist P: Composite endpoints: Proceed with
20. US Department of Health and Human Services
Food and Drug Administration, Center for Drug Evalua-
tion and Research (CDER), Center for Biologics Eval-
ation and Research (CBER): Guidance for industry: Clinical
trial endpoints for the approval of cancer drugs and
GuidanceComplianceRegulatoryInformation/Guidances/
ucm071590.pdf
etoposide chemotherapy in elderly patients with small-
cell lung cancer: Results of a randomized multicenter
phase II study assessing attenuated-dose or full-dose
with lenograstim prophylaxis—A Forza Operativa Nazion-
ale Italiana Carcinoma Polmonare and Gruppo Studio
Tumori Polmonari Veneto (FONICAP-GSTPV) study.
J Clin Oncol 23:569-575, 2005
22. National Cancer Institute: Cancer Therapy Evalua-
.gov/protocolDevelopment/electronic_applications/
ct.htm
factor in patients with advanced non-small cell lung
cancer treated with front-line docetaxel-gemcitabine
with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. Lancet
377:1749-1759, 2011
older French patients as willing as older American
patients to undertake chemotherapy? J Clin Oncol
21:3214-3219, 2003
26. Bottomley A, Vanvoorden V, Flechtnier H,
et al: The challenges and achievements involved in
implementing quality of life research in cancer clin-
27. Yellen SB, Cella DF, Leslie WT: Age and clinical
decision making in oncology patients. J Natl Can-
cer Inst 86:1766-1770, 1994
preting the significance of changes in health-related
opment of the European Organisation for Re-
search and Treatment of Cancer quality of life ques-
tionnaire module for older people with cancer: The
EORTC QLQ-ELD15. Eur J Cancer 46:2242-2252,
2010
ing treatments using quality-adjusted survival: The
tional status as a predictor of mortality: Results of a
32. Brain EG, Mertens C, Girre V, et al: Impact of
liposomal doxorubicin-based adjuvant chemotherapy
on autonomy in women over 70 with hormone-
receptor-negative breast carcinoma: A French Geriatric
Oncology Group (GERICO) phase II multicentre trial.
we operate? Preoperative assessment in elderly
cancer patients (PACE) can help—A SIOG surgical
task force prospective study. Crit Rev Oncol Hematol
80:160-170, 2011
34. Lewis JH, Kilgore ML, Goldman DP, et al: Par-
ticipation of patients 65 years of age or older in
cancer clinical trials. J Clin Oncol 21:1383-1389,
2003
35. Scher KS, Hurria A: Under-representation of older adults in cancer registration trials: Known
problem, little progress. J Clin Oncol 30:2026-2038,
2012
too old? Age should not be a barrier to enrollment in
cancer clinical trials. Oncologist 10:198-204, 2005
37. Peyrade F, Jardin F, Thieblemont C, et al:
Attenuated immunochemo therapy regimen (R-
miniCHOP) in elderly patients older than 80 years
with diffuse large B-cell lymphoma: A multicentre,
single-arm, phase 2 trial. Lancet Oncol 12:460-468,
2011
38. Wildiers H, Highley MS, de Bruijn EA, et al: Pha-
armacology of anticancer drugs in the elderly
ting chemotherapy toxicity in older adults with can-
29:3457-3465, 2011
40. Extermann M, Boler I, Reich RR, et al: Pre-
dicting the risk of chemotherapy toxicity in older
patients: The Chemotherapy Risk Assessment Scale for
High-Age Patients (CRASH) score. Cancer
118:3373-3386, 2012
41. Tucci A, Ferrari S, Bottelli C, et al: A compre-
hensive geriatric assessment is more effective than
clinical judgment to identify elderly diffuse large cell
lymphoma patients who benefit from aggressive
Diffuse large B-cell and peripheral T-cell non-
Hodgkin’s lymphoma in the frail elderly: A phase II
EORTC trial with a progressive and cautious treat-
ment emphasizing geriatric assessment. J Geriatr
Oncol 2:36-44, 2011
43. Puts MT, Hardt J, Monette J, et al: Use of
geriatric assessment for older adults in the oncology
setting: A systematic review. J Natl Cancer Inst
104:1134-1164, 2012
44. Balducci L, Extermann M: Management of the
frail person with advanced cancer. Crit Rev
Oncol Hematol 33:143-148, 2000
45. Muss HB, Berry DA, Currincone CT, et al: Adjuvant chemotherapy in older women with early-
stage breast cancer. N Engl J Med 360:2055-2065,
2009
study: What did we learn from the pilot phase. Br J
Cancer 105:1260-1266, 2011
47. Mohile SG, Wildiers H: A call for observational
cohort studies in geriatric oncology. J Geriatr Oncol
3:291-293, 2012
workshop on clinical trial methodology in older indi-
viduals with a diagnosis of solid tumors. Ann Oncol
49. Hurria A, Currincone CT, Muss HB, et al: Imple-
menting a geriatric assessment in cooperative group
cancer clinical trials: CALGB 360401. J Clin
Oncol 29:1290-1296, 2011
50. Cerretti F, Eichler HG, Rasi G: Drug policy for an
aging population: The European Medicines Agency’s
1974, 2012